Recursion Pharmaceuticals, Inc. (RXRX)

Name: Recursion Pharmaceuticals, Inc. (RXRX) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

SEC name RECURSION PHARMACEUTICALS, INC. · CIK 0001601830 · Nasdaq · Biological Products, (No Diagnostic Substances)

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Recursion Pharmaceuticals, Inc. reported revenue of $74.68M. Revenue grew 26.9% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $54.86M.

Key ratios (year ended 2025-12-31)

5.0%

Gross margin (computed)

-867.9%

Operating margin

-863.4%

Net margin

-57.0%

Return on year-end equity

26.9%

Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-15

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Revenue	$54.86M	$74.68M	$58.84M	$44.58M	$39.84M	$10.18M	$3.96M	$2.32M
Cost of Revenue	$52.94M	$70.95M	$45.24M	$42.59M	$48.27M	$0	$0	n/a
Gross Profit (computed)	$1.91M	$3.73M	$13.60M	$1.99M	-$8.43M	n/a	n/a	n/a
R&D Expense	$394.51M	$475.27M	$314.42M	$241.23M	$155.70M	$135.27M	$63.32M	$45.81M
Operating Income	-$544.01M	-$648.13M	-$479.00M	-$350.06M	-$245.73M	-$182.78M	-$84.61M	-$62.44M
Depreciation & Amortization	$78.36M	$83.70M	$36.49M	$24.40M	$11.76M	$8.40M	$3.94M	$2.49M
EBITDA	-$465.65M	-$564.43M	-$442.51M	-$325.66M	-$233.97M	-$174.37M	-$80.67M	-$59.95M
Net Income	-$518.88M	-$644.76M	-$463.66M	-$328.07M	-$239.48M	-$186.48M	-$87.01M	-$61.88M
EPS (Diluted)	n/a	-$1.44	-$1.69	-$1.58	-$1.36	-$1.49	-$3.99	-$2.87
Total Assets	$1.21B	$1.47B	$1.45B	$653.70M	$701.29M	$610.35M	$298.58M	n/a
Total Liabilities	$297.67M	$343.26M	$413.82M	$190.26M	$215.48M	$67.41M	$56.56M	n/a
Long-Term Debt	n/a	n/a	n/a	n/a	n/a	$723.0K	n/a	n/a
Shareholders' Equity	$915.00M	$1.13B	$1.03B	$463.44M	$485.81M	$542.94M	-$206.29M	-$124.27M
Cash & Equivalents	$545.68M	$743.29M	$594.35M	$391.56M	$549.91M	$285.12M	$262.13M	n/a
Operating Cash Flow	-$350.48M	-$371.81M	-$359.17M	-$287.78M	-$83.52M	-$158.61M	-$45.40M	-$57.04M
Capital Expenditures	$1.79M	$6.47M	$13.70M	$11.96M	$37.06M	$39.80M	$5.83M	$3.91M
Free Cash Flow	-$352.27M	-$378.28M	-$372.87M	-$299.74M	-$120.58M	-$198.41M	-$51.23M	-$60.95M
Shares Outstanding	534.12M	528.18M	396.80M	234.27M	191.02M	170.27M	22.31M	n/a
Weighted Average Diluted Shares	n/a	447.45M	274.21M	207.85M	175.54M	125.35M	21.78M	21.57M
EPS (Basic)	n/a	-$1.44	-$1.69	-$1.58	-$1.36	-$1.49	-$3.99	-$2.87

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView